Investor/Media Information

Press Release

Printer Friendly Version View printer-friendly version
<< Back
PlasmaTech Biopharmaceuticals To Present at 17th Annual BIO CEO & Investor Conference

DALLAS and NEW YORK, Feb. 6, 2015 /PRNewswire/ -- PlasmaTech Biopharmaceuticals, Inc. (PTBI), a biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, announced today that Scott Schorer, CEO, will be presenting a corporate update at the 17th Annual BIO CEO & Investor Conference.  The presentation will take place on Monday, February 9, 2015, at 5:00 pm ET in the Park South room at the Waldorf Astoria Hotel in New York, NY.  Management from PTBI is available throughout the conference for one-on-one meetings as well.

A copy of the presentation will be available on our corporate website at www.plasmatechbio.com.

About PlasmaTech Biopharmaceuticals, Inc.:  PlasmaTech Biopharmaceuticals, Inc. (PlasmaTech) is a biopharmaceutical company focused on advancing targeted treatments for significant unmet needs of critical patient care.  Exploiting two distinct proprietary platforms, Salt Diafiltration (SDF™) Process and Polymer Hydrogel Technology (PHT™), PlasmaTech is active in the development and commercialization of plasma-derived therapeutics and cancer supportive care products. The Company has developed a robust product pipeline that includes two commercial stage products, MuGard® and ProctiGard™ as well as multiple pre-clinical follow-on products. For more information visit, www.plasmatechbio.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: timelines and clinical results for MuGard and ProctiGard, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to PlasmaTech's need to obtain additional financing in order to continue clinical trials and operations and to the risks detailed in PlasmaTech's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission.

Company and Media Contact:
Harrison Wehner
President & CFO
PlasmaTech Biopharmaceuticals, Inc.
(617) 981-6955

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/plasmatech-biopharmaceuticals-to-present-at-17th-annual-bio-ceo--investor-conference-300032191.html